ORGANIC
LETTERS
2001
Vol. 3, No. 23
3699-3702
Automated Solid-Phase Synthesis of a
Branched Leishmania Cap
Tetrasaccharide
Michael C. Hewitt and Peter H. Seeberger*
Department of Chemistry, Massachusetts Institute of Technology,
Cambridge, Massachusetts 02139
Received August 22, 2001
ABSTRACT
Described is the first automated solid-phase synthesis of a branched oligosaccharide by stepwise assembly from monosaccharides. Cap
tetrasaccharide 1, found as part of the cell surface lipophosphoglycan (LPG) of the protozoan parasite Leishmania, was readily prepared using
glycosyl phosphate and glycosyl trichloroacetimidate building blocks.
Oligopeptides1 and oligonucleotides2 are routinely prepared
by automated solid-phase synthesis. Oligosaccharides con-
stitute the third major class of repeating biopolymers found
in nature and have been much more difficult to prepare.
Automated solid-phase synthesis and one-pot solution-phase
synthesis approaches for the preparation of these molecules
have only very recently been reported.3,4 Unlike peptides and
oligonucleotides, oligosaccharides are commonly encoun-
tered in highly branched form. In the first automated
oligosaccharide synthesis the branching points were installed
by incorporation of disaccharide building blocks to main-
tain the linear mode of assembly.3 The common occurrence
of branched motifs in carbohydrates of biochemical and bio-
medical significance prompted us to address this challenge.
endemic in the U.S.6,7 Lipophosphoglycans (LPG),8 which
are ubiquitous on the cell surface of Leishmania parasites,
are composed of a glycosylphosphatidylinositol (GPI) anchor,
a repeating phosphorylated disaccharide, and different cap
oligosaccharides (Figure 1). The branched tetrasaccharide at
the terminus of the LPG constitutes an attractive vaccine
target and has been previously synthesized in solution9 and
on solid support.9c While the initial immunological results
using the synthetic carbohydrate vaccine are promising,10
more rapid access to the carbohydrate portion of potential
vaccines would greatly facilitate such ventures.
(4) Zhang, Z.; Ollmann, I. R.; Ye, X.-S.; Wischnat, R.; Baasov, T.; Wong,
C.-H. J. Am. Chem. Soc. 1999, 121, 734.
(5) For a review, see: Herwaldt, B. L. Lancet 1999, 354, 1191.
(6) Magill, A. J.; Grogl, M.; Gasser, R. A.; Sun, W.; Oster, C. N. N.
Engl. J. Med. 1993, 328, 1383.
Leishmaniasis is a tropical disease that afflicts over 12
million people worldwide5 and is on the verge of becoming
(7) Alvar, J.; Canavate, C.; Gutierrez-Solar, B. et al. Clin. Microbiol.
ReV. 1997, 10, 298
(8) For a review, see: Turco, S. J.; Descoteaux, A. Annu. ReV. Microbiol.
(1) Atherton, A.; Sheppard, R. C. Solid-Phase Peptide Synthesis:
Practical Approach; Oxford University Press: Oxford, U.K., 1989.
(2) Caruthers, M. H. Science 1985, 230, 281.
A
1992, 46, 65.
(9) (a) Arasappan, A.; Fraser-Reid, B. J. Org. Chem. 1996, 61, 2401.
(b) Upreti, M.; Ruhela, D.; Vishwakarma, R. A. Tetrahedron 2000, 6577.
(c) Hewitt, M. C.; Seeberger, P. H. J. Org. Chem. 2001, 66, 4233.
(10) Schofield, L. Personal communication.
(3) Plante, O. J.; Palmacci, E. R.; Seeberger, P. H. Science 2001, 291,
1523.
10.1021/ol016631v CCC: $20.00 © 2001 American Chemical Society
Published on Web 10/25/2001